Fulgent Genetics SEC Filings

Fulgent Genetics (FLGT) reported an insider equity transaction by its Chief Financial Officer and Treasurer, Paul Kim. On 11/23/2025, 671 shares of common stock were withheld at a price of $30 per share to cover tax obligations that arose when previously granted restricted stock units vested. After this tax withholding transaction, Paul Kim beneficially owned 333,447 shares of Fulgent Genetics common stock directly. This filing documents a routine administrative event related to equity compensation rather than an open-market purchase or sale.

Fulgent Genetics, Inc. reported an insider transaction by its President and COO on a Form 4. On 11/24/2025, the officer sold 681 shares of common stock at a weighted-average price of $30.473. The filing explains that the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 23, 2023.

After this transaction, the officer beneficially owned 339,087 shares of Fulgent Genetics common stock directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust. The trust holdings are attributed because the officer serves on its investment committee, while disclaiming beneficial interest except for any pecuniary interest.

Fulgent Genetics (FLGT) insider transaction: the company’s Chief Scientific Officer reported a small sale of common stock tied to tax obligations. On 11/24/2025, the officer sold 535 shares of Fulgent Genetics common stock at a weighted-average price of $30.473 per share. The sale was coded as a disposition of securities in an open-market transaction.

According to the disclosure, these shares were sold solely to cover tax withholding that arose when previously granted restricted stock units vested. After this transaction, the officer reported beneficial ownership of 954,908 shares of Fulgent Genetics common stock, held directly.

Fulgent Genetics, Inc. (FLGT) president and COO reported insider transactions involving the company’s common stock. On 11/19/2025, the reporting person sold 10,000 shares of common stock at a weighted-average price of $29.0983 per share for year-end tax planning. On the same date, 10,000 shares were transferred as a gift to the James and Karena Xie Family Foundation, over which the reporting person has voting and investment power.

After these transactions, the reporting person directly owned 339,768 shares of Fulgent Genetics common stock and indirectly held 220,816 shares through The Hsieh Family Dynasty Trust. The filing reflects personal portfolio and charitable planning by a senior executive rather than changes to the company’s operations.

Fulgent Genetics (FLGT) filed its Q3 2025 10‑Q, showing higher revenue but continued losses as it invests in growth and therapeutics. Revenue rose to $84.1M from $71.7M a year ago, lifting gross profit to $35.5M. Operating loss narrowed year over year to $15.4M, and net loss attributable to Fulgent was $6.6M (basic and diluted EPS ($0.21)). For the nine months, revenue reached $239.3M with a net loss of $37.1M.

The laboratory services segment generated nearly all revenue; one customer accounted for 23% of quarterly sales. The therapeutic development segment recorded modest revenue and a meaningful adjusted operating loss as programs advance. The company recognized a $9.9M impairment on a non‑marketable equity investment during 2025.

Liquidity remained solid: cash and cash equivalents were $117.6M, with marketable securities of $258.2M short‑term and $411.8M long‑term as of September 30, 2025. Total assets were $1.21B against total liabilities of $93.8M. Operating cash flow was a use of $23.5M year‑to‑date, partly offset by $100.2M net cash provided by investing activities. The company repurchased $10.9M of common stock year‑to‑date. As of November 3, 2025, shares outstanding were 30,912,392.

Fulgent Genetics furnished an 8-K announcing that it issued a press release with financial results for the fiscal quarter ended September 30, 2025. The company also updated its investor presentation the same day.

The results press release is furnished under Item 2.02, and the updated presentation is furnished under Item 7.01. These materials are available as Exhibits 99.1 and 99.2. The information in Items 2.02 and 7.01 is being furnished and is not deemed filed or incorporated by reference except as expressly stated in future filings.

Fulgent Genetics (FLGT) — Form 4: The company’s Chief Scientific Officer reported a tax‑withholding transaction on 10/26/2025. 1,642 shares of common stock were withheld (code F) to cover taxes upon vesting of restricted stock units related to the November 7, 2022 merger. The withholding was recorded at a price of $23.74 per share.

After this administrative transaction, the reporting person beneficially owns 955,443 shares of FLGT common stock, held directly.

Fulgent Genetics (FLGT) — Form 4 insider transaction: the company’s CFO and Treasurer reported a tax-related share withholding tied to equity vesting. On 10/26/2025, 2,743 shares of common stock were withheld under transaction code F at a price of $23.74 to satisfy tax obligations upon the vesting of restricted stock units assumed in the November 7, 2022 merger agreement.

Following this administrative transaction, the reporting person beneficially owned 334,118 shares directly. This filing reflects routine tax withholding associated with stock-based compensation rather than an open-market purchase or sale.

Fulgent Genetics (FLGT) reported an insider transaction by its President and COO. On 10/26/2025, 4,353 shares of common stock were withheld at $23.74 per share to cover taxes upon the vesting of previously assumed restricted stock units (Transaction Code F).

After the transaction, the reporting person beneficially owned 359,768 shares directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust. The filing notes the reporting person disclaims beneficial interest in the trust except for any pecuniary interest.